• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于大数据的日本男性前列腺癌发病预测模型。

A big data-based prediction model for prostate cancer incidence in Japanese men.

机构信息

Department of Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto-City, Kyoto, 602-8566, Japan.

Department of Biostatistics, Kyoto Prefectural University of Medicine, Kyoto-City, Kyoto, Japan.

出版信息

Sci Rep. 2023 Apr 21;13(1):6579. doi: 10.1038/s41598-023-33725-8.

DOI:10.1038/s41598-023-33725-8
PMID:37085532
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10121595/
Abstract

To define a normal range for PSA values (ng/mL) by age and create a prediction model for prostate cancer incidence. We conducted a retrospective analysis using 263,073 observations of PSA values in Japanese men aged 18-98 years (2007-2017), including healthy men and those diagnosed with prostate cancer. Percentiles for 262,639 PSA observations in healthy men aged 18-70 years were calculated and plotted to elucidate the normal fluctuation range for PSA values by age. Univariable and multivariable logistic regression analyses were performed to develop a predictive model for prostate cancer incidence. PSA levels and PSA velocity increased with age in healthy men. However, there was no difference in PSA velocity with age in men diagnosed with prostate cancer. Logistic regression analysis showed an increased risk of prostate cancer for PSA slopes ranging from 0.5 to 3.5 ng/mL/year. This study provides age-specific normal fluctuation ranges for PSA levels in men aged 18-75 years and presents a novel and personalized prediction model for prostate cancer incidence. We found that PSA slope values of > 3.5 ng/mL/year may indicate a rapid increase in PSA levels caused by pathological condition such as inflammation but are unlikely to indicate cancer risk.

摘要

定义 PSA 值(ng/mL)的正常范围并建立前列腺癌发病的预测模型。我们对 2007-2017 年间 263073 例年龄在 18-98 岁的日本男性(包括健康男性和前列腺癌患者)的 PSA 值进行了回顾性分析。计算了年龄在 18-70 岁的健康男性中 262639 例 PSA 观察值的百分位数,并绘制图表以阐明 PSA 值随年龄的正常波动范围。对前列腺癌发病的预测模型进行了单变量和多变量逻辑回归分析。在健康男性中,PSA 水平和 PSA 速度随年龄的增长而增加。然而,在诊断患有前列腺癌的男性中,PSA 速度随年龄的变化没有差异。逻辑回归分析显示,PSA 斜率在 0.5 至 3.5ng/mL/年之间,前列腺癌发病的风险增加。本研究为年龄在 18-75 岁的男性提供了特定年龄的 PSA 水平正常波动范围,并提出了一种新的、个性化的前列腺癌发病预测模型。我们发现,PSA 斜率值>3.5ng/mL/年可能表示 PSA 水平因炎症等病理状况而快速升高,但不太可能表示癌症风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/10121595/3ee11226aee3/41598_2023_33725_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/10121595/cd99ba253378/41598_2023_33725_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/10121595/8d2761aec7ca/41598_2023_33725_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/10121595/3f75f593ea18/41598_2023_33725_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/10121595/3ee11226aee3/41598_2023_33725_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/10121595/cd99ba253378/41598_2023_33725_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/10121595/8d2761aec7ca/41598_2023_33725_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/10121595/3f75f593ea18/41598_2023_33725_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/10121595/3ee11226aee3/41598_2023_33725_Fig4_HTML.jpg

相似文献

1
A big data-based prediction model for prostate cancer incidence in Japanese men.基于大数据的日本男性前列腺癌发病预测模型。
Sci Rep. 2023 Apr 21;13(1):6579. doi: 10.1038/s41598-023-33725-8.
2
Ethnic differences in the age-related distribution of serum prostate-specific antigen values: A study in a Taiwanese male population.血清前列腺特异性抗原值与年龄相关的分布的种族差异:台湾男性人群的研究。
PLoS One. 2023 Mar 16;18(3):e0283040. doi: 10.1371/journal.pone.0283040. eCollection 2023.
3
Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.基于社区的健康男性人群中的血清前列腺特异性抗原。特定年龄参考范围的建立。
JAMA. 1993 Aug 18;270(7):860-4.
4
Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.在初次筛查时无疾病证据的荷兰和日本男性中,4年后前列腺癌的检测及前列腺特异性抗原水平升高。
Cancer. 2005 Jan 15;103(2):242-50. doi: 10.1002/cncr.20739.
5
Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy.前列腺癌基因 3(PCA3)尿液检测在日本男性前列腺活检中的临床应用。
BJU Int. 2013 May;111(6):928-33. doi: 10.1111/j.1464-410X.2012.11683.x. Epub 2013 Jan 18.
6
Clinical significance of prostate specific antigen for early stage prostate cancer detection.前列腺特异性抗原在早期前列腺癌检测中的临床意义。
Jpn J Clin Oncol. 1994 Jun;24(3):160-5.
7
Long-term longitudinal changes in baseline PSA distribution and estimated prevalence of prostate cancer in male Japanese participants of population-based PSA screening.基于人群的 PSA 筛查中日本男性参与者的基线 PSA 分布和前列腺癌预估患病率的长期纵向变化。
Int J Cancer. 2018 Oct 1;143(7):1611-1619. doi: 10.1002/ijc.31560. Epub 2018 May 14.
8
Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men.基于社区的健康日本男性人群中的血清前列腺特异性抗原:数值低于同龄白人男性。
Br J Urol. 1995 Mar;75(3):347-53. doi: 10.1111/j.1464-410x.1995.tb07347.x.
9
Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0 ng/mL equivalent to that in men with 4.1 to 10.0 ng/mL in a Japanese population.在日本人群中,前列腺特异性抗原水平为2.0至4.0 ng/mL的男性中前列腺癌的检测情况与前列腺特异性抗原水平为4.1至10.0 ng/mL的男性相当。
Urology. 2004 Apr;63(4):727-31. doi: 10.1016/j.urology.2003.11.025.
10
Distributions and characteristics of initial PSA and PSA velocity in Chinese men aged 50 years and younger without prostate cancer: a multi-center study.50岁及以下无前列腺癌中国男性的初始前列腺特异性抗原(PSA)水平及PSA速率的分布和特征:一项多中心研究
J BUON. 2019 Mar-Apr;24(2):832-837.

引用本文的文献

1
Transcriptomic signatures of prostate cancer progression: a comprehensive RNA-seq study.前列腺癌进展的转录组特征:一项全面的RNA测序研究。
3 Biotech. 2025 May;15(5):135. doi: 10.1007/s13205-025-04297-3. Epub 2025 Apr 19.

本文引用的文献

1
The Association between Prostate-Specific Antigen Velocity (PSAV), Value and Acceleration, and of the Free PSA/Total PSA Index or Ratio, with Prostate Conditions.前列腺特异性抗原速度(PSAV)、数值及增速与游离前列腺特异性抗原/总前列腺特异性抗原指数或比值与前列腺疾病之间的关联。
J Clin Med. 2020 Oct 23;9(11):3400. doi: 10.3390/jcm9113400.
2
Transcriptomics Signature from Next-Generation Sequencing Data Reveals New Transcriptomic Biomarkers Related to Prostate Cancer.来自下一代测序数据的转录组学特征揭示了与前列腺癌相关的新转录组学生物标志物。
Cancer Inform. 2019 Mar 13;18:1176935119835522. doi: 10.1177/1176935119835522. eCollection 2019.
3
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
欧洲前列腺癌筛查随机研究的 16 年随访。
Eur Urol. 2019 Jul;76(1):43-51. doi: 10.1016/j.eururo.2019.02.009. Epub 2019 Feb 26.
4
PSA kinetics before 40 years of age.40 岁前 PSA 动力学。
Int Braz J Urol. 2018 Nov-Dec;44(6):1114-1121. doi: 10.1590/S1677-5538.IBJU.2017.0710.
5
Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.中年时期前列腺特异性抗原水平与黑人男性侵袭性前列腺癌。
Eur Urol. 2019 Mar;75(3):399-407. doi: 10.1016/j.eururo.2018.08.032. Epub 2018 Sep 17.
6
Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.基于前列腺特异性抗原的前列腺癌筛查:美国预防服务工作组的证据报告和系统评价。
JAMA. 2018 May 8;319(18):1914-1931. doi: 10.1001/jama.2018.3712.
7
Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.基于风险的患者选择行 MRI 靶向前列腺活检可避免不必要的 MRI 扫描。此类患者为经直肠超声引导下前列腺随机活检阴性。
Eur Urol. 2016 Jun;69(6):1129-34. doi: 10.1016/j.eururo.2015.11.018. Epub 2015 Dec 2.
8
Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection Program.前列腺癌预测中年龄调整后的前列腺特异性抗原水平:蒂罗尔前列腺癌早期检测项目的更新结果
PLoS One. 2015 Jul 28;10(7):e0134134. doi: 10.1371/journal.pone.0134134. eCollection 2015.
9
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.前列腺癌筛查与死亡率:欧洲前列腺癌筛查随机研究(ERSPC)13年随访结果
Lancet. 2014 Dec 6;384(9959):2027-35. doi: 10.1016/S0140-6736(14)60525-0. Epub 2014 Aug 6.
10
Age-specific reference range of prostate-specific antigen and prostate cancer detection in population-based screening cohort in Japan: verification of Japanese Urological Association Guideline for prostate cancer.日本基于人群的筛查队列中前列腺特异性抗原的年龄特异性参考范围与前列腺癌检测:对日本泌尿外科学会前列腺癌指南的验证
Int J Urol. 2014 Nov;21(11):1120-5. doi: 10.1111/iju.12523. Epub 2014 Jun 15.